Multi-center randomized double-blind controlled study on children's anorexia (spleen-stomach disharmony) treated with Child Compound Endothelium Corneum / 中国中药杂志

Child Compound Endothelium Corneum(CCEC)has the effects in invigorating the spleen and appetizing the appetite, and dissolving the accumulation of food. The recent studies have proved that it could improve gastrointestinal motility, restore physiological gastrointestinal peristalsis, increase gastrointestinal digestive motility, and enhance appetite. This trial aimed to evaluate its clinical efficacy and safety in the treatment of children's anorexia(spleen-stomach disharmony). A total of 240 children with anorexia in line with the inclusion and exclusion criteria were selected and randomly divided into experimental group and control group, with 120 in each group. Patients in the experimental group took CCEC and Erpixing Granules simulant. Patients in the control group took Erpi-xing Granules and CCEC simulant. After 21 days of treatment, there was no statistical difference in the recovery rate of anorexia, reduced food intake, eating time, weight change, traditional Chinese medicine syndrome effect, single symptom effect, and trace element Zn recovery rate between the two groups. Based on the non-inferiority test, the experimental group was not inferior to the control group in efficacy. How-ever, the effect of CCEC in reducing appetite in children with anorexia was better than that of control drugs(P<0.05). There was no statistical difference in the incidence of adverse events and adverse reactions between the two groups during the trial. This experiment confirmed the efficacy and safety of CCEC in the treatment of children's anorexia(spleen-stomach disharmony), with a safety and re-liability in clinical application. In addition, it was a better choice for children with anorexia who were mainly manifested by reduced appetite. Meanwhile, compared with granule, chewable tablets were more convenient to take in clinic. Therefore, the efficacy and safety of CCEC for the treatment of children's anorexia(spleen-stomach disharmony) were not inferior to those of Erpixing Granules, with a safety and reliability in clnic. However, due to the small sample size of this trial, the efficacy results only show a trend. It is suggested to further carry out a large-sample-size clinical study to define the clinical advantages of CCEC.

Influence of argatroban on cerebral blood flow ,levels of CXCL16 and hsCRP in patients with acute cerebral infarction / 心血管康复医学杂志

Objective :To explore influence of argatroban on cerebral blood flow ,levels of CXC chemokine ligand 16 (CX-CL16) and high sensitive C reactive protein (hsCRP) in patients with acute cerebral infarction (ACI).Methods :A total of 100 ACI patients were selected ,randomly and equally divided into routine treatment group and argatroban group (received argatroban based on routine treatment ) ,both groups were treated for 10d.Score of United States national institutes of health stroke score (NIHSS) ,cerebral blood flow and levels of CXCL16 and hsCRP were compared between two groups be-fore and after treatment .Results :Compared with before treatment ,after treatment ,there were significant reductions in NIHSS score ,levels of endothelin (ET)-1 ,CXCL16 and hsCRP ,and significant rise in mean blood flow velocities of mid-dle cerebral artery (MCA) and anterior cerebral artery (ACA) and nitric oxide (NO) level in two groups (P＝0.001 all) ;compared with routine treatment group after treatment ,there were significant reductions in NIHSS [ (9.78 ± 3.59) scores vs.(7.02 ± 3.67) scores] ,levels of ET-1 [(75.75 ± 10.67) pg/ml vs.(62.56 ± 9.45) pg/ml] ,CXCL16 [(2.01 ± 0.84) ng/ml vs.(1.67 ± 0.75) ng/ml] and hsCRP [(4.42 ± 1.66) mg/L vs.(3.89 ± 1.37) mg/L] ,and significant rise in mean blood flow velocities of MCA [ (48.87 ± 5.23) cm/s vs.(55.35 ± 6.35) cm/s] and ACA [ (41.25 ± 4.89) cm/s vs. (47.88 ± 5.47) cm/s] and NO level [ (55.77 ± 6.36) μmol/L vs.(65.76 ± 6.86) μmol/L] in argatroban group , P＜0.05 or ＜0.01.There was no significant difference in incidence rate of hemorrhage events between two groups (P＝0.315). Conclusion : Argatroban based on routine treatment can more effectively improve cerebral blood flow and vascular endothe-lial function ,reduce levels of CXCL 16 and hsCRP ,and improve clinical therapeutic effect .

Time-order expression of caspase-3 and iNOS in contused human brain tissue / 法医学杂志

OBJECTIVE@#To investigate the expression of caspase-3 and iNOS in different intervals and to provide evidence for estimation of injury intervals after brain contusion in human.@*METHODS@#Thirty cases died of serious brain injury were included into the injury groups and 5 cases died of non-brain injury were served as control group. To analyze the changes of caspase-3 and iNOS expression in brain samples at different intervals (2h, 4-8h, 10-14h, 1-2d, 3-5d, 8-11d) by immunohistochemistry and auto-image analysis system.@*RESULTS@#The level of caspase-3 expression started to increase in 2 hours after brain contusion compared to the control group (P<0.05). The level of caspase-3 expression continued to increase in 1-2 days and maintained high level in 3-5 days compared to the control group (P<0.05), then decreased gradually. There was no statistically significant difference between the expression level of iNOS in 2 hours with the control group (P>0.05). But the expression level of iNOS began to increase in 4-8 hours after brain contusion and reached its maximum in 1-2 days, then decreased. Weak expression of iNOS still could be detected in 8-11 days.@*CONCLUSION@#The expression of caspase-3 and iNOS can be used as effective evidence for human brain contusion interval.